Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Glioblastoma 115Gliosarcoma 53Brain Neoplasms 53Glioma 47Central Nervous System Neoplasms 30Astrocytoma 29Melanoma 26Oligodendroglioma 14Neuroblastoma 10Neoplasm Metastasis 9Recurrence 7Ependymoma 7Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Skin Neoplasms 5Sarcoma, Ewing 5Lymphoma 5Breast Neoplasms 5Spinal Cord Neoplasms 4Somatostatinoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Lung Neoplasms 3Gastrinoma 3Carcinoma, Islet Cell 3Uveal Melanoma 2Rhabdomyosarcoma 2

Interventions

Everolimus 5Topotecan 2Etoposide 2Cisplatin 2Bevacizumab 2veliparib 1pralsetinib 1pertuzumab 1pembrolizumab 1pasireotide 1lenvatinib 1carfilzomib 1cabozantinib 1berzosertib 1Temozolomide 1Sunitinib 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Podophyllotoxin 1Platinum 1Octreotide 1Nivolumab 1Magnetic Resonance Spectroscopy 1Irinotecan 1Ipilimumab 1Carboplatin 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Neuroendocrine × Temozolomide × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡